To establish a deficit-neutral reserve fund relating to requiring the Comptroller General of the United States to conduct a study related to economic consequences of private or confidential drug pricing agreements struck by any Federal department, agency, or office with any pharmaceutical manufacturer.

This legislation directs the Government Accountability Office (GAO) to conduct a comprehensive study examining the economic impact of private or confidential drug pricing agreements between federal agencies and pharmaceutical companies. Currently, many of these government-negotiated contracts are shielded from public view, making it difficult to assess whether taxpayers are getting the best value for pharmaceutical products or how these secret deals influence broader market prices. By establishing a deficit-neutral reserve fund to support this audit, the bill aims to increase transparency in federal spending. For Arlington residents, this oversight could lead to a better understanding of how federal healthcare procurement drives drug costs, potentially influencing future policy reforms that seek to lower prescription prices and improve overall market fairness in the healthcare sector.